The factor VIII complex in atherosclerosis: Effects of aspirin

David Green*, Omer Kucuk, Olga Haring, Alan Dyer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Sixty patients with well-documented previous myocardial infarction were treated with either 1 gm of aspirin daily or a placebo (AMIS trial). The factor VIII-von Willebrand factor complex was measured at 3-4-month intervals during the first 12-16 months of the trial. The levels of the complex did not change appreciably during this period, and the mean values for all but seven patients fell within 2 S.D. of the mean values obtained in normal laboratory controls. The concentrations of the factor VIII-von Willebrand complex in patients with a variety of vascular occlusive events did not differ from those in patients without such events. Finally, the mean values in patients treated with aspirin were virtually identical to those receiving placebo. We conclude that plasma levels of the factor VIII-von Willebrand factor complex are not altered in patients with atherosclerotic vascular disease, and are unaffected by aspirin therapy.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalJournal of chronic diseases
Volume34
Issue number1
DOIs
StatePublished - 1981

ASJC Scopus subject areas

  • Epidemiology

Fingerprint Dive into the research topics of 'The factor VIII complex in atherosclerosis: Effects of aspirin'. Together they form a unique fingerprint.

Cite this